Incyte | INCY - Cost Of Sales


Incyte reported $104.96M in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 28.32M 3.52M Jun/2026
Agenus USD 642K 399K Sep/2025
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Alnylam Pharmaceuticals USD 298.45M 87.33M Jun/2026
Amgen USD 1.87B 271M Jun/2026
BioCryst Pharmaceuticals USD 3.84M 5.68M Jun/2026
Biogen USD 945.1M 147.6M Jun/2026
BioMarin Pharmaceutical USD 276.29M 76.8M Jun/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Eli Lilly USD 3.27B 309M Jun/2026
Exelixis USD 19.95M 6.53M Mar/2026
Gilead Sciences USD 1000M 445M Jun/2026
Incyte USD 104.96M 457K Jun/2026
Ionis Pharmaceuticals USD 2.74M 261K Jun/2026
MacroGenics USD 9.53M 585K Mar/2026
Merck USD 3.14B 200M Jun/2026
Moderna USD 93M 862M Jun/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 39.4M 25.6M Jun/2026
Novartis USD 3.71B 251M Jun/2026
Novartis USD 3.46B 83M Mar/2026
Pfizer USD 4.09B 498M Jun/2026
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 576.5M 92.9M Jun/2026
Sarepta Therapeutics USD 150.1M 40.64M Jun/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vertex Pharmaceuticals USD 489.2M 96.4M Jun/2026